Search
Ospemifene
go.drugbank.com/drugs/DB04938ApprovedOspemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause … FDA approved on February 26, 2013.
Meningococcal polysaccharide vaccine group C
go.drugbank.com/drugs/DB13890ApprovedInvestigational*N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. … It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Mixtures: Menjugate 10 Mikrogramm Injektionssuspension in einer Fertigspritze, MENVEO POWDER & SOLUTION FOR SOLUTION FOR INJECTIONMisoprostol
go.drugbank.com/drugs/DB00929ApprovedInvestigationalMisoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions. … [A181586] Misoprostol was granted FDA approval on 27 December 1988.[L7616]
Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)Birch bark extract
go.drugbank.com/drugs/DB16536ApprovedInvestigational[L42390] Filsuvez was subsequently approved for the same indication by the US FDA in December 2023. … [L50031] The EMA marketing authorization for Episalvan[L42370] was withdrawn by the manufacturer in 2022.
Futibatinib
go.drugbank.com/drugs/DB15149ApprovedInvestigational[L43347] On July 4, 2023, the European Commission granted Conditional Marketing Authorization for futibatinib for the treatment of cholangiocarcinoma.[L47800] … [A253193,A253198] As a novel inhibitor of FGFR, futibatinib was first approved by the FDA in September 2022 to treat different types of intrahepatic cholangiocarcinoma.
Synonyms: 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-oneTepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalTepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February … In February 2022, tepotinib was approved for use in Europe.[L42200]
Shark liver oil
go.drugbank.com/drugs/DB11088ApprovedShark oil is extracted from the livers of sharks, which can account for up to 25% of their total body weight. … However the major component is considered to be squalene, which may range up to 90% of the shark oil, depending on the species.
Mixtures: Rx Act Hemorrhoidal, Formulation R Hemorrhoidal OintmentBrincidofovir
go.drugbank.com/drugs/DB12151ApprovedInvestigationalCidofovir itself has broad antiviral activity against several DNA viruses,[A235725] resulting in brincidofovir being investigated for the prevention and treatment of cytomegalovirus (CMV), BK Virus (BKV … The approval was granted under the agency’s Animal Rule,[L34480] which allows for a drug to be approved based on the results of well-controlled animal studies when human trials would be unethical or infeasible
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseQuazepam
go.drugbank.com/drugs/DB01589ApprovedIllicitQuazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. … [L44913] It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other
Doxepin
go.drugbank.com/drugs/DB01142ApprovedInvestigational[L5977] Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant.[L5971] However, in 2010 it was approved for the treatment of insomnia. … [T83] In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline
Categories: Antidepressive Agents Indicated for Depression, Non-Selective Monoamine Reuptake Inhibitors